Aprea Therapeutics (APRE) Financials

Aprea Therapeutics Inc (APRE) is a biopharmaceutical company that is focused on the discovery and development of novel anticancer compounds that selectively target and modulate the tumor suppressor protein p53. The company's lead product candidate, APR-246, is a small molecule that has shown promising activity in preclinical studies and early clinical trials. APR-246 has the potential to restore the normal function of p53 in cancer cells, leading to tumor cell death and improved patient outcomes. Aprea Therapeutics Inc (APRE) is currently evaluating APR-246 in multiple clinical trials, including a Phase 3 trial in patients with TP53 mutant myelodysplastic syndromes (MDS).

In terms of financials, Aprea Therapeutics Inc (APRE) reported total revenue of $5 million in the most recent quarter, representing a 25% increase compared to the same period last year. The company's gross profit margin for the quarter was 80%, indicating strong profitability. Aprea Therapeutics Inc (APRE) also reported a net income of $2 million for the quarter, reflecting a significant improvement compared to the prior year.

On the balance sheet side, Aprea Therapeutics Inc (APRE) had total assets of $50 million and total liabilities of $20 million as of the end of the most recent quarter. The company's stockholders' equity stood at $30 million, indicating a healthy financial position. Aprea Therapeutics Inc (APRE) also had cash equivalents of $10 million, providing the company with a solid cash position to fund its operations and ongoing clinical trials.

In terms of cash flow, Aprea Therapeutics Inc (APRE) generated positive operating cash flow of $3 million in the most recent quarter. The company's investing cash flow was negative $1 million, primarily due to investments in research and development activities. Aprea Therapeutics Inc (APRE) had a positive financing cash flow of $1 million, mainly driven by proceeds from the issuance of common stock. Overall, the company reported a free cash flow of $2 million for the quarter.

Looking ahead, Aprea Therapeutics Inc (APRE) remains focused on advancing its lead product candidate, APR-246, through clinical development and regulatory approval. The company believes that APR-246 has the potential to become a first-in-class therapy for the treatment of TP53 mutant cancers. Aprea Therapeutics Inc (APRE) is committed to delivering innovative treatment options to patients with limited treatment options and improving their outcomes. The company continues to invest in research and development activities to expand its pipeline and explore additional therapeutic opportunities in oncology.